Marcin Wichary, the author of Shift Happens — an exhaustively researched, beautifully designed and photographed history of the keyboard — is back with a deep dive into Gorton, a font found on ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...

Despite recent surprise competition from the likes of DeepSeek, OpenAI remains the biggest name in AI right now. The company ...

OpenAI reveals a sleek rebrand featuring a refined logo, custom typeface, and cohesive design, blending human creativity with ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

ChatGPT-maker OpenAI unveiled a new logo, typeface (font), and color palette in a rebranding push. Although the changes are not very drastic, ...

Does Warren Buffett Know Something That Wall Street Doesn't? The Billionaire Investor Is Piling Into a High-Yield Stock That Certain Analysts Recommend Selling. Kimbal Musk sells Tesla stock worth ...

Wondering what typeface was used in any given video game? Charlotte Couderc's Game Font Library is exactly what it claims to be. You can search by game, genre, studio, typeface or even foundry. Game ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung ...